<DOC>
	<DOCNO>NCT00849329</DOCNO>
	<brief_summary>This study characterize effect elevate gastric pH mediate proton-pump inhibitor , esomeprazole , relative bioavailability lapatinib subject metastatic ErbB2 positive breast cancer .</brief_summary>
	<brief_title>A Study Examine Effects Esomeprazole Pharmacokinetics Orally Administered Lapatinib Subjects With Metastatic ErbB2 Positive Breast Cancer</brief_title>
	<detailed_description />
	<mesh_term>Breast Neoplasms</mesh_term>
	<mesh_term>Esomeprazole</mesh_term>
	<mesh_term>Lapatinib</mesh_term>
	<criteria>Metastatic , histologically confirm breast cancer overexpresses ErbB2 ( 3+ IHC , FISH , CISH positive ) . 18 year 65 year age . Is male female ( non childbearing potential willing use contraception specify protocol ) . Is able swallow retain oral medication . ECOG performance status 0 2 . Provided write informed consent . Adequate bone marrow function ( specify protocol ) . Calculated creatinine clearance ( CrCl ) great equal 50 ml/min base Cockcroft Gault . Total bilirubin less equal 1.5 X upper limit normal institutional value . Alanine transaminase ( ALT ) less equal 3 time upper limit institutional value less equal 5 time ULN document liver metastasis Has leave ventricular ejection fraction ( LVEF ) within normal institutional range base ECHO MUGA . Life expectancy great equal 12 week Capable give write informed consent , include compliance requirement restriction list consent form . Pregnant lactate woman . Has malabsorption syndrome , disease affect gastrointestinal function , resection stomach small bowel . Has current active hepatic biliary disease ( exception patient Gilbert 's syndrome , asymptomatic gallstone , liver metastasis stable chronic liver disease per investigator assessment ) Has evidence symptomatic uncontrolled brain metastasis leptomeningeal disease . Subjects brain metastasis treat surgery and/or radiotherapy eligible neurologically stable require steroid anticonvulsant . Is consider medically unfit study investigator . Has know immediate delay benzimidazole hypersensitivity reaction idiosyncrasy drug chemically relate investigational product gefitinib [ Iressa ] erlotinib [ Tarceva ] . Has receive treatment investigational drug previous four week . ( exception lapatinib ) . Has receive chemotherapy , immunotherapy , biologic therapy hormonal therapy treatment cancer within past 14 day , exception mitomycin C restrict past six week , lapatinib . Subjects receive lapatinib prior study entry eligible participate study . Is receive prohibit medication within timeframe indicate prohibited medication list protocol . Has physiological , familial , sociological , geographical condition permit compliance protocol . Has inadequate venous access protocolrelated blood draw . Clinically significant electrocardiogram abnormality . History sensitivity heparin heparininduced thrombocytopenia . Consumption red wine , seville orange , grapefruit grapefruit juice and/or kumquat , pummelo , exotic citrus fruit ( i.e . star fruit , bitter melon ) , grapefruit hybrid fruit juice seven day prior first dose study medication .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>65 Years</maximum_age>
	<verification_date>March 2011</verification_date>
	<keyword>lapatinib ( GW572016 ) , subject , pharmacokinetic , esomeprazole , proton-pump inhibitor , drug interaction , Phase 1</keyword>
</DOC>